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Abstract
Background: Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor
or protease inhibitor may not be suitable for a subset of antiretroviral-naïve patients such as those with
certain co-morbidities, women of child-bearing potential, and intolerability to components of standard first
line therapy. This study was conducted to determine if alternate treatment options may meet the needs
of both general and special patient populations. The ACTION study was a randomized, open-label,
multicenter, 48-week trial that compared the safety and efficacy of a triple nucleoside regimen versus a
protease inhibitor plus a dual nucleoside regimen in HIV-1 treatment-naïve subjects.
Results: 279 HIV-infected subjects with HIV-1 RNA (VL) >5000 but < 200,000 copies/mL (c/mL) and
CD4+ count ≥ 100 cells/mm3 were randomized (1:1) to receive abacavir sulfate/lamivudine/zidovudine
(ABC/3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-
daily. Protocol-defined virologic failure was based on multiple failure criteria.
Non-inferiority of ABC/3TC/ZDV to ATV+3TC/ZDV was established with 62% vs. 59% of subjects
achieving a VL < 50 c/mL at week 48, [ITT(E), M/S = F, 95% CI: -5.9, 10.4]. Similar results were observed
in the 230 (82%) subjects with baseline VL<100,000 c/mL (ABC/3TC/ZDV vs. ATV+3TC/ZDV), 66% vs.
59%; 95% CI: -5.6, 19.5. However, ABC/3TC/ZDV did not meet the non-inferiority criterion compared to
ATV+3TC/ZDV in the 48 subjects with baseline VL ≥ 100,000 c/mL, 39% vs. 60%; 95% CI: -49.2, 7.4,
respectively. Protocol-defined virologic failure was similar between groups.
Conclusion:  ABC/3TC/ZDV demonstrated comparable virologic efficacy to ATV+3TC/ZDV in this
population over 48 weeks. In those with a baseline VL ≥ 100,000 c/mL, subjects in the ATV+3TC/ZDV
showed better virologic efficacy. Both regimens offer benefits in select therapy-naïve subjects.
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Background
For the majority of ART-naïve, HIV-1 infected patients, the
choice of an initial antiretroviral regimen continues to
contain either a non-nucleoside reverse transcriptase
inhibitor (NNRTI) or a boosted protease inhibitor (PI) in
combination with two nucleoside reverse transcriptase
inhibitors (NRTIs) [1]. However, there is an important
subset of patients for which these first line regimens are
unsuitable for a variety of reasons including presence of
co-morbidities such as metabolic syndrome, underlying
severe depression, drug-drug interactions, inability to tol-
erate low-dose ritonavir, and women of child-bearing
potential. Additionally, as the population ages, patients
are more likely to be on polypharmacy. For these groups
of patients, it is important to select a regimen that is both
individualized and provides suitable efficacy and safety
compared to first-line regimens. The present study was
conducted to determine if alternate treatment options
may meet the needs of both general and special patient
populations.
Triple NRTI therapy with the fixed dose combination of
abacavir sulfate, lamivudine and zidovudine (ABC 300
mg, 3TC 150 mg, ZDV 300 mg; Trizivir® GlaxoSmithKline,
Research Triangle Park, NC) has several advantages to
other HAART regimens including convenience to facilitate
adherence, low pill burden, no food or water restrictions,
generally favorable safety and metabolic profile, and few
drug-drug interactions. The safety and efficacy of abacavir
sulfate, lamivudine, and zidovudine (ABC/3TC/ZDV) or
its components have been demonstrated in several rand-
omized trials of ART-naïve subjects [2-4].
Study CNA3014 was an open-label, randomized, multi-
center trial comparing triple nucleoside therapy with
abacavir sulfate (ABC 300 mg; Ziagen®, GlaxoSmithKline,
Research Triangle Park, NC) plus fixed dose lamivudine/
zidovudine (3TC 150 mg, ZDV 300 mg; Combivir®, Glax-
oSmithKline, Research Triangle Park, NC) both adminis-
tered twice-daily (BID) versus indinavir (IDV) thrice-daily
+ 3TC/ZDV BID in ART-naïve subjects. At week 48, 60%
of subjects in the ABC+3TC/ZDV group and 50% in the
IDV+3TC/ZDV group achieved a plasma HIV-1 RNA (VL)
<50 c/mL. In stratified analyses, results were similar
among groups regardless of screening VL (< or ≥ 100,000
c/mL) in contrast to lower virologic responses observed
with ABC+3TC/ZDV in subjects with VL >100,000 c/mL in
an earlier double-blind, placebo-controlled study,
CNAAB3005 [2,3].
Study ESS40002 was a randomized, open-label, three-
arm, international, 96-week trial that evaluated 1) ABC/
3TC/ZDV, 2) NFV+3TC/ZDV, and 3) NFV+3TC+stavudine
(d4T) in a racially diverse ART-naive population of which
50% were female. Through 96 weeks, 41% vs. 39% vs.
33% of ABC/3TC/ZDV, NFV+3TC/ZDV, and
NFV+3TC+d4T treated subjects, respectively, achieved a
VL <50 c/mL. Subjects with a low baseline VL (<100,000
c/mL) responded comparably regardless of randomized
treatment. In contrast, subjects in the ABC/3TC/ZDV
group with a higher baseline VL (>100,000 but <200,000
c/mL) demonstrated greater virologic response (53%)
compared with NFV+3TC/ZDV (29%) and NFV+3TC+d4T
(42%) at week 96 [4].
The AIDS Clinical Trial Group (ACTG) 5095 study team
found that triple nucleoside therapy with ABC/3TC/ZDV
resulted in a significantly shorter time to virologic failure
regardless of baseline viral load when compared to a
pooled EFV-containing regimen of ABC/3TC/ZDV and
3TC/ZDV [5]. At week 48, 61% of subjects receiving ABC/
3TC/ZDV compared with 83% on pooled EFV-containing
regimens achieved an HIV-1 RNA <50 c/mL, the superior
virologic response of the latter attributable to EFV. Inferior
virologic responses among subjects randomized to the
ABC/3TC/ZDV arm resulted in early termination of this
study arm and removal of triple nucleoside regimens as a
first-line therapy option from the US Department of
Health and Human Services (DHHS) guidelines in ART-
naïve subjects [6]. Surprisingly, this trend had not been
observed in earlier trials with ABC/3TC/ZDV when com-
pared to PI-based regimens with baseline VL up to
300,000 c/mL [2,3]. Therefore, given the totality of data
on the safety, tolerability, and efficacy of ABC/3TC/ZDV
compared to other initial ART regimens and consistent
with the DHHS Guidelines, the combination of ABC/
3TC/ZDV remains a reasonable option for the treatment
of select ART-naïve subjects.
Atazanavir sulfate (ATV; Reyataz®, Bristol-Myers Squibb,
Princeton, NJ) is a protease inhibitor that may also be a
useful alternative therapy option in select patient popula-
tions. Atazanavir has several attributes including once-
daily (QD) administration without ritonavir in ART-naïve
subjects and a favorable lipid profile. However, scleral
icterus and jaundice secondary to bilirubin elevations
have been reported in subjects receiving atazanavir [7].
The safety and efficacy of atazanavir has been demon-
strated in several randomized trials. Study AI424-034 was
a pivotal, randomized, double blind, multicenter trial
comparing atazanavir QD versus efavirenz QD each in
combination with the 3TC/ZDV fixed-dose combination
tablet BID. Through 48 weeks of therapy, 32% vs. 37% of
subjects treated with ATV+3TC/ZDV vs. EFV+3TC/ZDV
maintained viral suppression below 50 c/mL [8].
In a select population of ART-naïve HIV-1 infected sub-
jects with low viral loads, ABC/3TC/ZDV and ATV+3TC/
ZDV may offer similar benefits versus ritonavir-boosted PI
or NNRTI-containing regimens. Therefore in the ACTIONAIDS Research and Therapy 2009, 6:3 http://www.aidsrestherapy.com/content/6/1/3
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study, [Clinical Trials Identifier, NCT00082394], we com-
pared the safety, tolerability, and efficacy of ABC/3TC/
ZDV versus atazanavir plus 3TC/ZDV over 48 weeks in
ART-naïve HIV-1 infected subjects with baseline VL ≥
5000 and <200,000 c/mL.
Methods
Study Design
ESS100327 was a phase IV, randomized, non-inferiority,
open-label, 48 week study comparing a fixed dose combi-
nation triple nucleoside regimen containing abacavir sul-
fate, lamivudine, and zidovudine (ABC/3TC/ZDV)
administered twice-daily to a protease inhibitor based reg-
imen of atazanavir (ATV) administered once daily with a
fixed dose tablet of two nucleosides, lamivudine and zido-
vudine (3TC/ZDV), administered twice daily. Patients
were recruited from 46 sites in the USA and Mexico and
were eligible for enrollment if they were infected with
HIV-1, aged 18 years or older, ART-naïve and had plasma
HIV-1 RNA ≥ 5000 but <200,000 c/mL and CD4+ cell
count ≥ 100 cells/mm3. Subjects were excluded if they had
medical conditions or required medications that could
compromise their safety or interfere with drug absorption,
or if they had protocol-specific abnormal laboratory val-
ues.
This study was approved by ethics committees at each par-
ticipating site and all subjects provided written informed
consent. The study was conducted in accordance with
Good Clinical Practice.
Treatment allocation was based on a central randomiza-
tion schedule stratified by screening HIV-1 RNA (< or ≥
100,000 c/mL). Patients were randomized 1:1 to receive
either ABC/3TC/ZDV as one tablet twice daily (BID) or 2–
200 mg capsules of ATV once daily (QD) plus one tablet
of 3TC/ZDV administered BID. Subjects randomized to
ABC/3TC/ZDV and diagnosed with a suspected abacavir
hypersensitivity reaction (ABC HSR) were permitted a
switch to 3TC/ZDV BID + tenofovir disoproxil fumarate
(TDF) 300 mg QD. Subjects randomized to ATV+3TC/
ZDV who experienced ATV treatment-limiting toxicity
(specifically jaundice or scleral icterus secondary to
bilirubin elevations) were permitted a switch to fosampre-
navir calcium (FPV) 1400 mg BID + 3TC/ZDV BID.
Assessments and Outcomes
Patients were evaluated at screening, Day 1 (baseline),
and at weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48 and
withdrawal. Clinical and laboratory assessments includ-
ing HIV-1 viral load, CD4+/CD8+ lymphocyte subsets,
clinical chemistry, hematology, serum lipid panels, insu-
lin, and hemoglobin A1C were performed regularly
throughout the study. Insulin resistance and sensitivity
were assessed on fasting subjects periodically using the
homeostasis model assessment of insulin resistance
(HOMA-IR) and the quantitative insulin-sensitivity check
index (QUICKI), respectively. US Centers for Disease
Control and Prevention (CDC) classification was assessed
and samples for hepatitis B and C serology and pregnancy
tests were performed at baseline and at investigator discre-
tion, where appropriate. Plasma for genotypic drug resist-
ance testing was collected at baseline and at any
confirmatory visits for virologic failure.
HIV-1 RNA was measured by the Roche COBAS Amplicor
HIV-1 Monitor test, Version 1.5 and the Roche COBAS
Amplicor HIV-1 Ultrasensitive Monitor test, Version 1.5
(Branchburg, NJ, USA). Genotypic analyses were per-
formed by GlaxoSmithKline Clinical Virology (Research
Triangle Park, NC) using the TruGene HIV-1 Genotyping
assay and by Monogram Biosciences (South San Fran-
cisco, CA, USA) using the Phenosense HIV assay, respec-
tively. All other laboratory testing was performed centrally
by Quest Laboratories (Van Nuys, CA, USA).
The primary efficacy endpoint was the proportion of sub-
jects with HIV-1 RNA <50 c/mL at week 48 who did not
meet the definition of virologic failure through week 48
using an intent-to-treat exposed analysis [ITT(E)]. Due to
the concerns raised by the ACTG 5095 study, multiple,
stringent criteria for protocol-defined virologic failure was
established as shown in Table 1. The primary safety end-
points were the frequency of treatment-limiting adverse
events, Grade 2–4 adverse events, and serious adverse
events over 24 and 48 weeks.
Secondary endpoints included the proportion of subjects
with HIV-1 RNA <50 c/mL at weeks 24 and 48 in those not
meeting protocol-defined virologic failure. Subjects with
regimen switches for suspected ABC HSR or ATV treat-
ment-limiting toxicity were analyzed as treatment failures
(switch = failure, S = F) and in sensitivity analyses in
which the switch was not treated as a failure. Additional
secondary endpoints included proportion of subjects with
HIV-1 RNA <400 c/mL at weeks 24 and 48, change in
plasma HIV-1 RNA and CD4+ cell count from baseline,
time to loss of virologic response (TLOVR), change in fast-
ing lipids, insulin, and glucose, adherence, and develop-
ment of genotypic and phenotypic resistance at virologic
failure.
Statistical Analysis
Efficacy and safety analyses included all subjects that were
treated before withdrawal (intent-to-treat exposed
[ITT(E)]). Assuming a success rate of 0.58 for the ABC/
3TC/ZDV BID group and 0.50 for the ATV QD + 3TC/ZDV
BID group, a total of 280 (140 subjects per treatment arm)
provided greater than 90% power (one-sided, α = 0.025)
to establish non-inferiority of ABC/3TC/ZDV comparedAIDS Research and Therapy 2009, 6:3 http://www.aidsrestherapy.com/content/6/1/3
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to ATV+3TC/ZDV using a 12% non-inferiority margin.
Non-inferiority was established if the lower limit of the
two-sided 95% confidence interval for the difference in
proportions (ABC/3TC/ZDV BID – ATV QD + 3TC/ZDV
BID) exceeded -12%.
The primary analysis was ITT(E) where missing or regi-
men switches for ABC HSR or ATV treatment-limiting tox-
icity were treated as failures (M/S = F). Additional analyses
included ITT(E), M = F where the regimen switches were
not treated as failures. Observed analyses in which miss-
ing data was not imputed were also performed with and
without the regimen switches treated as failures. For the
primary efficacy analysis and the corresponding sensitiv-
ity analyses, the treatment response rates in each group
were stratified by the baseline HIV-1 RNA (< or ≥ 100,000
c/mL) using Mantel-Haenszel weights. Exploratory analy-
ses in each baseline viral load stratum were also per-
formed.
Descriptive statistics were used to evaluate the secondary
efficacy endpoints. ITT(E) and Observed analyses were
carried out for the proportions of subjects with plasma
HIV-1 RNA < 400 c/mL and < 50 c/mL at week 48 using
M/S = F and M = F, overall and stratified by baseline viral
load stratum. Kaplan-Meier estimates were calculated for
the time to first study-defined virologic failure and the
time to loss of virologic response (TLOVR).
The safety population included all randomized patients
who consumed at least one dose of study drug and were
analyzed by the actual treatment received. Adverse events
(AEs) were graded by the investigator according to the
Division of AIDS toxicity table (1992) and coded by an
adverse event dictionary (MedDRA) [9]. Grade 2–4 AEs
(moderate to severe in intensity), treatment-related AEs,
and serious AEs were collected. No statistical inferences
were performed for these summaries. Changes from base-
line in fasting insulin levels, HOMA-IR, QUICKI, and
lipid profiles (total cholesterol, high-density lipoprotein,
low-density lipoprotein, and triglycerides) were tabu-
lated.
Adherence was calculated as the ratio of the total number
of doses taken to the total number of doses that should
have been taken. The numerator of the ratio was calcu-
lated as the number of tablets dispensed minus the
number of tablets returned.
Genotypic summaries were based on differences in the
plasma virus sequence from the molecular wild-type
strain NL4-3. Reverse transcriptase (RT) and protease
(PRO) mutations associated with the development of
resistance to antiretroviral therapy as listed by the Interna-
tional AIDS Society (IAS) Drug Resistance Mutation
Group were used in the analyses [10].
All analyses were performed using SAS® v8 (SAS Institute,
Cary, NC) on a system of UNIX computers.
Results
Study Population
Two hundred and seventy-nine (279) subjects were
enrolled between May 2004 and March 2005; and the
ITT(E) population consisted of 278 subjects. Table 2 sum-
marizes the demographics and baseline characteristics,
which were well-matched between the treatment groups.
Overall, the study population was predominantly male
(79%) and racially diverse (>50% non-white race or eth-
nicity). Most subjects (82%) had an HIV-1 RNA <100,000
c/mL at baseline. Seven subjects (5%) in the ABC/3TC/
ZDV group and 9 subjects (6%) in the ATV+3TC/ZDV
group were included in the switch population for sus-
pected ABC hypersensitivity and ATV treatment-limiting
toxicities, respectively. No pregnancies or deaths occurred
during the study.
Subject disposition through 48 weeks is shown in Figure
1. Data from 3 subjects in the ABC/3TC/ZDV group were
not retrievable due to Hurricane Katrina damage in
Table 1: Virologic Failure Definition
Prior to or at Week 24
1. Failure to have ≥ 1 log HIV-1 RNA drop from baseline by week 12
2. Reduction of plasma HIV-1 RNA to <50 copies/mL on two occasions followed by increase of ≥ 400 copies/mL on two consecutive times prior to 
week 24*
3. Failure to have <400 copies/mL by week 24
After Week 24
4. Plasma HIV-1 RNA ≥ 400 copies/mL on two consecutive occasions after week 24*
5. Subject had an HIV-1 RNA ≥ 400 copies/mL at week 48 with confirmation
* virologic rebound any time at or after confirmed virologic failure of ≥ 1265 copies/mL on two consecutive occasions resulted in subject's 
discontinuation from the study as a virologic withdrawal.AIDS Research and Therapy 2009, 6:3 http://www.aidsrestherapy.com/content/6/1/3
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August 2005. In addition, subjects that met the protocol-
defined definition of virologic failure were permitted to
remain on study if their VL remained less than 1265 c/mL
(1/2 log above 400 c/mL). Thus, some subjects appear
twice in the summary of study outcome (Table 3), as viro-
logic failures and as study completers. Overall, 74% of
subjects in the ABC/3TC/ZDV group and 70% of subjects
in ATV+3TC/ZDV group completed the study.
Efficacy
The non-inferiority of ABC/3TC/ZDV to ATV+3TC/ZDV
was established since 62% (85/138) vs. 59% (83/140) of
subjects achieved an HIV-1 RNA <50 c/mL and were con-
sidered virologic responders in the primary efficacy analy-
sis at week 48, [ITT(E), M/S = F, 95% CI: -5.9, 10.4]
(Figure 2). Similarly, in the Observed analysis, 76% (85/
112) vs. 74% (83/112) of subjects in the ABC/3TC/ZDV
group vs. ATV+3TC/ZDV group achieved a VL<50 c/mL at
week 48, [ITT(E), S = F 95% CI: -6.7, 9.4].
In exploratory stratified analyses, similar results were
observed in the 230 subjects with baseline VL<100,000 c/
mL (ABC/3TC/ZDV vs. ATV+3TC/ZDV), 66% (76/115) vs.
59% (68/115); 95% CI: -5.6, 19.5, suggesting that ABC/
3TC/ZDV was virologically non-inferior to ATV+3TC/ZDV
in the low viral load stratum (Figure 3). In contrast,
among the 48 subjects with baseline VL ≥ 100,000 c/mL
(ABC/3TC/ZDV vs. ATV+3TC/ZDV), 39% (9/23) vs. 60%
(15/25) achieved a VL<50 c/mL at week 48; 95% CI: -49.2,
7.4, suggesting that ABC/3TC/ZDV did not meet the non-
inferiority criterion compared to ATV+3TC/ZDV in the
high viral load stratum. Further, the confidence interval
suggests that ATV+3TC/ZDV was non-inferior to ABC/
3TC/ZDV in the high viral load stratum of this study.
Comparable results were seen in stratified Observed anal-
yses at week 48 (ABC/3TC/ZDV vs. ATV+3TC/ZDV);
<100,000 c/mL stratum (81% vs. 76%; 95% CI: -7.5,
16.4) and ≥ 100,000 c/mL stratum (50% vs. 65%; 95% CI:
-46.2, 15.8). Sensitivity analyses demonstrated no differ-
ences in efficacy when subjects with missing data resulting
from Hurricane Katrina were excluded.
Secondary analyses of the primary efficacy endpoint in
which subjects with toxicity switches were not considered
failures, for both the overall population and by viral load
strata, resulted in consistent results for both the M = F and
observed examinations. At week 48, 67% (93/138) vs.
68% (95/140) of subjects in the ABC/3TC/ZDV vs.
ATV+3TC/ZDV group achieved a VL < 400 c/mL [ITT(E),
M = F] (Figure 2). Similar results were seen in the
Observed analysis; 92% (93/101) vs. 96% (95/99) of sub-
jects in ABC/3TC/ZDV vs. ATV+3TC/ZDV group, respec-
tively. The proportion of subjects (ABC/3TC/ZDV vs.
ATV+3TC/ZDV) that achieved a VL < 50 c/mL when toxic-
ity switches were not considered failures was 64% (89/
138) vs. 63% (88/140) [ITT(E), M = F] and 80% in each
treatment group [(89/111) vs. (88/110)] in Observed
analyses, respectively (Figure 3).
Immunologic recovery was observed in both treatment
groups at week 48. The median change from baseline in
CD4+ cell count was an increase of 147 cells/mm3 in both
groups resulting in a median CD4+ cell count of 434 cells/
mm3 in the ABC/3TC/ZDV group and 419 cells/mm3 in
the ATV+3TC/ZDV group.
Protocol-defined virologic failure occurred in 18 (13%)
vs. 17 (12%) of subjects in the ABC/3TC/ZDV vs.
ATV+3TC/ZDV group, respectively (Table 4). Three sub-
jects in the ABC/3TC/ZDV group and 6 subjects in the
Table 2: Baseline Demographics and Characteristics
ABC/3TC/ZDV (N = 139) ATV+3TC/ZDV (N = 140)
Median Age, years (range) 38 (19–65) 36 (18–68)
Female Gender, n (%) 30 (22%) 28 (20%)
Race, n (%)
White 65 (47%) 58 (41%)
Black 44 (32%) 49 (35%)
American Hispanic 26 (19%) 29 (21%)
Other 4 (3%) 4 (3%)
CDC Class C, n (%) 6 (4%) 5 (4%)
Median HIV-1 RNA, log10 copies/mL (range) 4.48 (2.3–5.5) 4.64 (2.6–5.6)
HIV-1 RNA ≥ 100,000 copies/mL, n (%) 24 (17%) 25 (18%)
Median CD4+ cell count, (cells/mm3) (range) 274 (103–889) 262 (50–749)
CD4+ cell count ≥ 200 cells/mm3, n (%) 105 (76%) 97 (69%)
Hepatitis B positive, n (%) 2 (1%) 6 (4%)
Hepatitis C positive, n (%) 9 (6%) 10 (7%)
Hepatitis & B positive, n (%) 0 1 (<1%)
Abbreviations: abacavir sulfate (ABC), atazanavir (ATV), lamivudine (3TC), zidovudine (ZDV)AIDS Research and Therapy 2009, 6:3 http://www.aidsrestherapy.com/content/6/1/3
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ATV+3TC/ZDV group met multiple virologic failure crite-
ria. Overall, subjects were more likely to experience viro-
logic rebound after week 24 in the ATV+3TC/ZDV group
while more subjects in the ABC/3TC/ZDV group had a VL
> 400 c/mL without confirmation at week 48. Regardless
of strata, a similar proportion of subjects experienced pro-
tocol-defined virologic failure independent of treatment
arm. As noted in Figure 4, no difference in time to loss of
virologic response between treatment groups was
observed. Additionally, adherence to randomized therapy
was high (median >97.5%) in both groups.
Safety
The safety population consisted of 278 subjects (138
ABC/3TC/ZDV; 140 ATV+3TC/ZDV) who were analyzed
based on treatment received. One subject randomized to
ABC/3TC/ZDV was dispensed ATV+3TC/ZDV for the
duration of the study and was analyzed based on the
actual treatment received. The overall incidence of Grade
2–4 adverse events was similar between arms; 72% in
each group. Treatment-related Grade 2–4 adverse events
occurred less frequently in the ABC/3TC/ZDV group with
notably different toxicities between groups (Table 5).
Hyperbilirubinemia was the most frequently reported
adverse event occurring in 21% of subjects in the
ATV+3TC/ZDV group followed by nausea in 11% of sub-
jects in the ABC/3TC/ZDV group and 4% of subjects in the
ATV+3TC/ZDV group. Treatment-related serious adverse
events were reported by 10 subjects (7 ABC/3TC/ZDV; 3
ATV+3TC/ZDV). Suspected abacavir hypersensitivity reac-
tions (ABC HSR) were considered serious adverse events
and were reported in 7 (5%) subjects receiving ABC/3TC/
Subject Disposition Figure 1
Subject Disposition.
457 screened
279 randomized
278 in Intent to Treat, Exposed 
Population  
178 subjects did not randomize 
1 subject did not consume drug  
138 randomized to ABC/3TC/ZDV  140 randomized to ATV+3TC/ZDV 
35 (25%) prematurely discontinued 
6 (4%) adverse events 
12 (9%) lost to follow-up 
2 (1%) consent withdrawn 
9 (7%) virologic failure 
6 (4%) other reasons 
41 (29%) prematurely discontinued
11 (8%) adverse events 
14 (10%) lost to follow-up 
1 (<1%) consent withdrawn 
10 (11%) virologic failure 
3 (2%) investigator decision 
2 (1%) protocol violation 
 
Study completion status was missing 
for 1 subject 
103 (74%) completed Week 48 98 (70%) completed Week 48 AIDS Research and Therapy 2009, 6:3 http://www.aidsrestherapy.com/content/6/1/3
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Table 3: Study Outcomes at Week 48
ABC/3TC/ZDV (N = 138) ATV+3TC/ZDV (N = 140)
Completed study 103 (74%) 98 (70%)
Prematurely withdrawn1 36 (26%) 41 (29%)
Virologic Failures 18 (13%) 17 (12%)
Primary Reason for Withdrawal2, n (%)
Adverse event 6 (4%) 11 (8%)
Lost to follow-up 12 (9%) 14 (10%)
Protocol defined virologic failure3 16 (12%) 16 (11%)
Subject decision 3 (2%) 1 (<1%)
Protocol violation 0 2 (1%)
Investigator decision 0 3 (2%)
Other4 6 (4%) 0
1. One subject in the ATV+3TC/ZDV group had a missing completion status.
2. As reported by study investigators on Study Conclusion case report form.
3. Subjects with confirmed virologic failure with subsequent HIV-1 RNA < 1265 copies/mL were allowed to remain in the study on randomized 
treatment; therefore the actual number of virologic failures is greater than the number that withdrew from study. In the ABC/3TC/ZDV group, 7 
virologic failures completed the study and 2 were lost to follow-up. In the ATV+3TC/ZDV group, 6 virologic failures completed the study and 1 was 
withdrawn with a protocol violation.
4. Other included (number of subjects): incarceration (2), site not operational due to Hurricane Katrina (3), moved out of state (1).
Proportion of subjects with HIV-1 RNA <50 and <400 copies/mL through Week 48 Figure 2
Proportion of subjects with HIV-1 RNA <50 and <400 copies/mL through Week 48. Proportion of patients with 
HIV-1 RNA < 50 copies/mL (solid line) and < 400 copies/mL (dashed line): ITT(E), M/S = F analysis.
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Proportion of subjects with HIV-1 RNA <50 copies/mL by baseline HIV-1 RNA at Week 48 Figure 3
Proportion of subjects with HIV-1 RNA <50 copies/mL by baseline HIV-1 RNA at Week 48. Analyses include 
switch equal to failure (top) and switch not equal to failure (bottom).
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Time to loss of virologic response (<50 copies/mL) Figure 4
Time to loss of virologic response (<50 copies/mL).
Table 4: Summary of Protocol-Defined Virologic Failure and Drug Resistance at Week 48
ABC/3TC/ZDV 
(N = 138)
ATV+3TC/ZDV 
(N = 140)
Virologic Responders 120 (87%) 123 (88%)
Protocol-Defined Virologic Failures 18 (13%) 17 (12%)
1. Less than 1 log10 reduction in baseline plasma HIV-1 RNA by week 12 3 3
2. Reduction of plasma HIV-1 RNA < 50 copies/mL on two occasions with a subsequent increase 
to ≥ 400 copies/mL on two consecutive occasions prior to week 24
22
3. Failure to achieve plasma HIV-1 RNA < 400 copies/mL by Week 24 3 4
4. Plasma HIV-1 RNA ≥ 400 copies/mL on consecutive occasions after Week 24 6 11
5. Plasma HIV-1 RNA ≥ 400 copies/mL at Week 48 without confirmation 7 3
Subjects meeting multiple virologic failure criteria1 35
Post-Baseline Genotype and Phenotype 17 16
Subjects with treatment-emergent mutations 10 11
Any NRTI-associated Mutations2 89
(M184V, M184M/V, L74V, L74I/V D67N, L210W)
Any PI-associated mutations 76
(G16E, K20M, L24I, L33V, I54I/L, I62V, V77I, I85I/V, I93I/L)
Any NNRTI-associated mutations 01
(K103N)
Note: Genotype at screening was not performed.
1. In the ABC/3TC/ZDV group, 1 subject met both criteria 2 and 5 and 2 subjects met both criteria 4 and 5; In the ATV+3TC/ZDV group, 1 subject 
met criteria 2 and 4, 3 subjects met criteria 3 and 4, and 1 subject met criteria 4 and 5.
2. Treatment-emergent mutations that were considered non-significant that also developed included: F77L, I13V, L63L/P, L63P, and E35G.AIDS Research and Therapy 2009, 6:3 http://www.aidsrestherapy.com/content/6/1/3
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ZDV of which 6 were classified as Grade-2 and 1 as a
Grade-1 event; none of the subjects experiencing a sus-
pected ABC HSR discontinued study. In the ATV+3TC/
ZDV group, 3 (2%) subjects reported anemia (2-Grade 3,
1-Grade 4) each requiring blood transfusions, two of
whom discontinued from study.
Treatment-emergent Grade 3–4 laboratory abnormalities
were infrequent and generally comparable between
groups (Table 5). Grade 3–4 hyperbilirubinemia occurred
in 15% of subjects treated with ATV+3TC/ZDV. Two sub-
jects discontinued study for atazanavir-related treatment
toxicities, 1 for jaundice and 1 for hyperbilirubinemia.
Additionally, 4 subjects receiving atazanavir elected to
Table 5: Grade 2–4 Treatment-Related Adverse Events & Laboratory Abnormalities Occurring in ≥ 2% of Subjects
ABC/3TC/ZDV (N = 138) ATV+3TC/ZDV (N = 140)
Any Grade 2–4 event (Grade 3–4) 30% (7%) 47% (25%)
Hyperbilirubinemia 0 21% (15%)
Nausea 11% (<1%) 4% (0)
Headache 4% (<1%) 4% (0)
Neutropenia 4% (4%) 5% (4%)
Fatigue 5% (<1%) 2% (0)
Suspected Abacavir Hypersensitivity1 5% (0) 0
Vomiting 2% (0) 2% (0)
Anemia <1% (<1%) 3% (3%)
Ocular Icterus 0 4% (2%)
Abdominal pain 2% (0) <1% (0)
Increased Creatinine Phosphokinase 0 2% (1%)
Rash 0 2% (0)
1 Includes 1 report of a Grade-1 suspected abacavir hypersensitivity reaction
Table 6: Median Fasting Lipid and Metabolic Parameters at Baseline and Week 48
ABC/3TC/ZDV
N = 138
ATV+3TC/ZDV
N = 140
Median (range) Number Tested
(Baseline, Week 48)
Baseline Week 48 Number Tested
(Baseline, Week 48)
Baseline Week 48
TC (mg/dL) 131, 93 162
(95–255)
176
(102–305)
137, 93 160
(71–276)
171
(68–288)
LDL (mg/dL) 127, 89 98
(6–165)
99
(20–198)
133, 92 97
(31–200)
101.5
(10–200)
HDL (mg/dL) 131, 93 36.5
(6–74)
44
(21–75)
135, 93 33
(7–77)
44
(18–90)
TG (mg/dL) 131, 93 113 
(38–621)
126
(42–1231)
137, 93 117 (41–559) 110
(44–407)
Glucose (mg/dL) 119, 91 95
(60–199)
98
(5–268)
126, 93 89.5
(58–131)
95
(72–166)
Insulin (μIU/mL) 117, 79 10
(2–128)
13
(2–56)
119, 83 10
(2–61)
12
(4–132)
HOMA-IR+ 110, 83 2.2
(0.4–37.5)
2.9
(0.4–17.3)
112, 87 2.4
(0.4–19.5)
3
(0.9–51.6)
QUICKI++ 110, 83 0.59
(0.34–1.05)
0.54
(0.38–1.00)
112, 87 0.58
(0.37–1.00)
0.54
(0.32–0.77)
+HOMA-IR = [Fasting Insulin (μIU/mL) × Fasting Glucose (mg/dL))/(22.5 × 18)];
++QUICKI = 1/[log Fasting Insulin (μIU/mL)] + [log Fasting Glucose (mg/dL)]AIDS Research and Therapy 2009, 6:3 http://www.aidsrestherapy.com/content/6/1/3
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switch to fosamprenavir for asymptomatic, grade 3 hyper-
bilirubinemia without clinical evidence of jaundice or
scleral icterus. Grade 3–4 neutropenia was reported in 10
subjects; 4% ABC/3TC/ZDV; 4% ATV+3TC/ZDV. Changes
in fasting lipids and glucose were comparable in both
treatment groups (Table 6). At week 48, median triglycer-
ides were 126 mg/dL in the ABC/3TC/ZDV group com-
pared with 110 mg/dL in the ATV+3TC/ZDV group.
However, all median fasting lipid parameters were below
NCEP ATP III thresholds for both groups at week 48
[11,12]. Changes in glucose, insulin sensitivity and insu-
lin resistance were minimal and comparable between
groups. The use of concurrent lipid lowering medications
was minimal; 5 subjects received statins (2 ABC/3TC/
ZDV; 3 ATV+3TC/ZDV) and 1 subject in the ABC/3TC/
ZDV group received a fibrate.
There were no myocardial infarctions reported in the
ABC/3TC/ZDV arm. Two cases of non-cardiac chest pain
(both confirmed by a negative diagnostic evaluation)
were reported in the ABC/3TC/ZDV arm. In the ATV +
3TC/ZDV arm, 1 case of confirmed myocardial infarction/
coronary occlusion was reported. All 3 cases were reported
as not-related to study drug.
Viral Resistance
Thirty-five subjects (13%) [18 ABC/3TC/ZDV; 17
ATV+3TC/ZDV] met one or more protocol-defined viro-
logic failure criteria. Paired genotypes and phenotypes
were available for 17/18 subjects in the ABC/3TC/ZDV
group and 16/17 subjects in the ATV+3TC/ZDV group at
baseline and at the time of virologic failure (Table 4).
Among the 35 subjects with virologic failure, 11.4% had
primary NRTI or NNRTI mutations and 5.7% had primary
PI-associated resistance mutations at baseline. Three sub-
jects (2 ABC/3TC/ZDV and 1 ATV+3TC/ZDV) with viro-
logic failure had primary ABC- and/or 3TC-related
mutations at baseline. Primary PI mutations were present
at baseline in 2 subjects experiencing virologic failure [1
D30N (ABC/3TC/ZDV); 1 L90M (ATV+3TC/ZDV)] and
the NNRTI-associated K103N mutation was present in 1
subject receiving ATV+3TC/ZDV. Treatment-emergent
ABC- and/or 3TC-associated mutations occurred in 10
subjects failing ABC/3TC/ZDV, the majority of which
developed the M184V mutation and to a lesser extent,
minor PI mutations suggesting these subjects had virus
harboring PI drug-resistance at baseline. In the ATV+3TC/
ZDV group, 11 subjects had treatment-emergent muta-
tions; 11 subjects developed the M184V nucleoside muta-
tion, 1 subject developed K103N, and 6 subjects
developed minor PI mutations. No major ATV-related
mutations developed over 48 weeks.
Treatment-emergent drug resistance occurred in subjects
experiencing virologic failure in both treatment arms.
Among the 35 subjects (13%) experiencing virologic fail-
ure, the M184V mutation developed most commonly in
46% (16/35) of subjects. Among subjects with paired phe-
notypic data, 45% (15/33) had no drug-associated
reduced susceptibility present while 55% (18/33) had
reduced phenotypic susceptibility present on treatment.
No subject had primary PI resistance at the time of viro-
logic failure as defined by IAS-USA guidelines [10]. These
results suggest that subjects failing on either treatment reg-
imen may have therapy options available given that cross-
resistance to other members in the nucleoside and pro-
tease inhibitor classes was not seen.
Discussion
ACTION was one of the first studies to evaluate the safety
and efficacy of ABC/3TC/ZDV compared to atazanavir,
the latter which was approved approximately 1 year prior
to initiation of present study. This study demonstrated the
virologic non-inferiority of ABC/3TC/ZDV compared to
ATV+3TC/ZDV in this study population over 48 weeks.
Virologic and immunologic responses were similar
between the treatment arms (ABC/3TC/ZDV vs.
ATV+3TC/ZDV) given 62% vs. 59% of subjects achieved
an HIV-1 RNA <50 c/mL and the median CD4+ cell count
increase was 147 cells/mm3 in both groups at week 48.
Similar responses were also evident in subjects with a
lower baseline viral load, as 66% and 59% of subjects in
the ABC/3TC/ZDV group and ATV+3TC/ZDV group
achieved the primary endpoint. However, virologic
response was suboptimal in the ABC/3TC/ZDV (39%)
group of subjects with a higher baseline viral load (≥
100,000 c/mL) compared to those in the ATV+3TC/ZDV
group (60%). The small number of subjects in the higher
viral load strata did not account for the large difference
between treatment arms since the study was stratified a
priori. However, atazanavir in combination with lamivu-
dine/zidovudine performed well regardless of baseline
viral load.
The rate of virologic failure was somewhat higher than
expected in this study in both treatment arms, likely due
to the use of multiple criteria for virologic failure, (13%
ABC/3TC/ZDV; 12% ATV+3TC/ZDV). A conservative def-
inition of virologic failure was adopted partly in response
to the results of the ACTG 5095 study and subsequent
change in the Department of Health and Human Services
guidelines for antiretroviral therapy reserving triple nucle-
oside regimens as alternative first line options. Differen-
tial treatment responses with ABC/3TC/ZDV in patients
with higher baseline viral loads have been observed rarely;
reduced responses were first observed in those with higher
baseline VL (>100,000 c/mL) when compared to a PI-
based regimen in Study CNA3005, and more recently inAIDS Research and Therapy 2009, 6:3 http://www.aidsrestherapy.com/content/6/1/3
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the ACTG 5095 study which demonstrated an inferior
virologic response of ABC/3TC/ZDV compared to pooled
EFV-containing arms with dual and triple nucleoside
backbones regardless of pre-treatment VL (< or ≥ 100,000
c/mL) [2,5].
Since no one particular virologic failure criteria was met
more often than another and reported medication adher-
ence was high, this suggests that subjects receiving ABC/
3TC/ZDV are not more likely to experience early virologic
non-response than virologic response followed by viral
rebound. For select subjects with baseline VL < 100,000 c/
mL, this study demonstrated that subjects receiving ABC/
3TC/ZDV have an equal opportunity for achieving viro-
logic success as those receiving an ATV-containing regi-
men without low-dose ritonavir boosting.
The unexpected appearance of treatment-emergent PI
mutations among subjects receiving ABC/3TC/ZDV may
have been attributed to the emergence of virus harboring
low levels of PI mutations undetectable at baseline from
either prior PI experience or acquisition of drug-resistance
virus. Similarly, the development of the K103N mutation
in a subject receiving ATV+3TC/ZDV suggests virus with
prior exposure to NNRTIs. Phenotypic resistance toward
either treatment regimen was observed infrequently sug-
gesting that subjects failing either treatment may have
within-class therapy options available given that cross-
resistance to other members in the nucleoside and pro-
tease inhibitor classes was not seen.
Both regimens were generally well-tolerated and a compa-
rable number of subjects, 4% vs. 8%, discontinued study
resulting from adverse effects in the ABC/3TC/ZDV vs.
ATV+3TC/ZDV group, respectively. Investigators were per-
mitted to switch patients off atazanavir for the manage-
ment of asymptomatic hyperbilirubinemia as per practice
in previous initial studies conducted by BMS [13].
Changes in fasting lipids and metabolic parameters were
minimal in this study. Median triglycerides were some-
what higher in the ABC/3TC/ZDV group compared to the
ATV+3TC/ZDV group (126 vs. 110 mg/dL); increases in
total cholesterol (176 vs. 171 mg/dL) were driven by favo-
rable increases in HDL cholesterol, however, all other
lipid parameters were essentially unchanged from base-
line. The minimal changes in fasting lipids are of limited
clinical significance given all parameters were below target
NCEP ATP III recommendations and were similar to other
published reports [8,14-16]. No differences in serum fast-
ing glucose, insulin, HOMA-IR or QUICKI were observed
between treatment arms over 48 weeks.
A fixed dose combination of ABC/3TC/ZDV provides an
effective, generally well-tolerated, and simplified triple
nucleoside regimen for select antiretroviral naïve subjects
with baseline viral loads < 100,000 c/mL. This dosing reg-
imen may be advantageous as an alternative regimen for
subjects with pre-existing co-morbidities, history of poly-
pharmacy with drug-drug interaction potential for whom
an NNRTI or PI-containing regimen would be challeng-
ing. For select patients who cannot tolerate the recom-
mended first line therapy options, both ABC/3TC/ZDV
and ATV+3TC/ZDV have demonstrated both efficacy and
safety in this study conferring an important role for these
therapies in both newly HIV-1 infected adults as well as in
the aging HIV-1 infected population of the United States.
Conclusion
A fixed dose combination of ABC/3TC/ZDV provides an
effective, generally well-tolerated, and simplified triple
nucleoside regimen for select antiretroviral naïve subjects
with baseline viral loads < 100,000 c/mL. This dosing reg-
imen may be advantageous as an alternative regimen for
subjects with pre-existing co-morbidities, history of poly-
pharmacy with drug-drug interaction potential for whom
an NNRTI or PI-containing regimen would be challeng-
ing. For select patients who cannot tolerate the recom-
mended first line therapy options, both ABC/3TC/ZDV
and ATV+3TC/ZDV have demonstrated both efficacy and
safety in this study conferring an important role for these
therapies in both newly HIV-1 infected adults as well as in
the aging HIV-1 infected population of the United States.
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